NasdaqGS:BBIOBiotechs
Will BridgeBio’s (BBIO) US$390 Million Raise and Late‑Stage Pipeline Progress Change Its Narrative?
BridgeBio Pharma, Inc. recently completed a US$390.0 million follow-on equity offering at US$78 per share, while reporting second-quarter 2026 revenue of US$243.68 million and a net loss of US$152.22 million, alongside updated results for the six months to June 30, 2026.
At the same time, BridgeBio highlighted extensive new clinical and real-world data for Attruby (acoramidis) and advanced its rare-disease pipeline with regulatory progress for BBP-418 and encaleret, underlining how fresh...